| Objective To observe the clinical efficacy and safety in the treatment of hyp ertension between ARB and ACEI,and conduct the pharmacoeconomics evalua te to choose the best treatment plan for hypertension patients.Method 1.A total of 206 cases of hypertensive patients who met the inclusi on criteria in January 2012 were collected in a third hospital in Haikou,using the method of objective sampling.To observe the indexes of blood pressure,heart rate and adverse reaction,and analyze the cost,influence factors,effect a nd influence factors of the patients.The cost-effectiveness analysis method was used to evaluate the cost-effectiveness of the different combined antihypertensi ve regimens,and the cost was compared with the difference effect,and the eff ect analysis and sensitivity analysis were carried out.2.The Markov model is used to simulate the multiplicative analysis and Mark ov queue.According to the literature review and the statistical data obtained i n China,the health utility value of all kinds of state and its medical expenses,the Markov model state transfer probability and so on.Reselts After treatment,drop in blood pressure in group ARB and group A CEI were reduced to(16.94±23.86)/(23.83±22.28)of SBP,(5.55±15.58)/(8.84±14.1)of DBP.Blood pressure control fates reached 69.9 in group ARB and 74.8 i n group ACEI.Conclusion 1.arb+ diuretics and acei+ diuretics have significant economic a nd clinical benefits in antihypertensive therapy,and acei+ diuretics can maximi ze the utilization of effective medical resources in the case of guaranteeing cur ative effect.2.Markov model has good application in the long-term pharmacoeconomics eva luation of antihypertensive therapy. |
PDF Full Text Request